Otros idiomas Pulse Biosciences, Inc.

Acciones

PLSE

US74587B1017

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 30/04/2024			Varia. Cinco días.	Varia. 1 de enero.
7,37 ^USD	+1,66 %		+7,43 %	-39,79 %

01/04	Actualización del sector: Las acciones del sector sanitario caen a última hora de la tarde	MT
01/04	Las acciones de Pulse Biosciences caen tras los resultados del 4º trimestre y los planes de emisión de derechos	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	24/04
Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28/03
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14/03
Sector Update: Health Care Stocks Ease Late Afternoon	08/03
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	08/03
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Pulse Biosciences, Inc.

Acciones

PLSE

US74587B1017

Otros idiomas

Filtros